EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation

Daria Maria Filippini, Christophe Le Tourneau

Translational Oncology · 2026-05 · 67 · 102715

DOI: 10.1016/j.tranon.2026.102715 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Oncology, 2026-05. Verfasst von Daria Maria Filippini und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy, with limited survival improvements despite recent advances with immune checkpoint inhibitors (ICIs). Within this context, personalized neoantigen vaccines and HPV-targeted therapeutic vaccines are emerging as innovative strategies aimed at enhancing antitumor immunity. Personalized vaccines exploit tumor-specific mutational landscape to generate highly individualized T cell responses, demonstrating favorable safety profiles and durable immunogenicity in early-phase trials. Compounds such as TG4050, mRNA-4157, and PGV001 have shown early, hypothesis-generating signals of activity (from small early-phase studies), particularly in the adjuvant setting. HPV-targeted vaccines, including PDS0101, BNT113, and CUE-101, are being explored in HPV-positive HNSCC, mainly in combination with ICIs. While some early clinical activity has been observed, these signals should be interpreted cautiously given limited sample sizes, heterogeneous populations, and exploratory endpoints in many studies, and randomized trials such as ISA101b have failed to show survival benefits over ICIs alone. Overall, therapeutic vaccination appears safe and immunologically active, yet its efficacy is constrained by the immunosuppressive tumor microenvironment. The greatest clinical potential of therapeutic vaccination may lie in earlier disease stages, where the tumor burden is lower and immune modulation more feasible. Further clinical and translational research is needed to define the optimal integration of vaccine-based therapies into multimodal treatment paradigms for HNSCC.

Schlagwörter

Stichwörter der Autor:innen

HPV therapeutic vaccinesHead and neck cancerImmunotherapyPersonalized neoantigen vaccinestumor microenvironment

Autor:innen und Institutionen

  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U1331 Research unit, Saint-Cloud, France; Paris-Saclay University, Paris, France. Electronic address: christophe.le-tourneau@gus…

Zitieren

APA

Filippini, D. M., & Le Tourneau, C. (2026). Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation. Translational Oncology, 67, 102715. https://doi.org/10.1016/j.tranon.2026.102715

Vancouver

Filippini DM, Le Tourneau C. Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation. Translational Oncology. 2026;67:102715. doi:10.1016/j.tranon.2026.102715

BibTeX
@article{Filippini2026,
  author = {Filippini, Daria Maria and Le Tourneau, Christophe},
  title = {Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation},
  journal = {Translational Oncology},
  year = {2026},
  volume = {67},
  pages = {102715},
  doi = {10.1016/j.tranon.2026.102715}
}
Kostenlos starten →